Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.2c00860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Ji Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Southeast University, Nanjing 14122, PR China. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Jiangsu Provincial Key Research and Development Program, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing 14122, PR China.
ORCID-Profile: Xinsong Li
Förderung
- Jiangsu Provincial Key Research and Development Program
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Wang, J., Zhang, Y., Liu, C., Zha, W., Dong, S., Wang, Y., Jiang, Y., Xing, H., & Li, X. (2023). Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c00860
Vancouver
Wang J, Zhang Y, Liu C, Zha W, Dong S, Wang Y, et al. Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.2c00860
BibTeX
@article{Wang2023,
author = {Wang, Ji and Zhang, Yanhao and Liu, Chao and Zha, Wenhui and Dong, Shuo and Wang, Yang and Jiang, Yuhao and Xing, Hanlei and Li, Xinsong},
title = {Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.2c00860}
}
EUVIMED